戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 hen schizophrenia onsets 3-5 years after smoking assessment were censored.
2                                       Data for all patients were censored 1 year post-study or death, whichever came firs
3                     Whereas 1975 patients received a KT and were censored, 1876 were on the waiting list at any time.
4 y where everyone with a prior history of any MACE before MI were censored and adjusted for follow-up times.
5 observing from a worldwide network of computers which texts were censored and which were not.
6                   Patients were followed up until death and were censored at 5 years if they were still alive.
7 es, 29% used PrEP prior to enrollment, 89 (3%) withdrew and were censored at date of withdrawal, leaving 2892 (97.0%) enr
8                                                       Cases were censored at death or liver transplantation and had a med
9                                                    Patients were censored at death, at 56 days, or at last contact if los
10                                      Time-to-event analyses were censored at first date of new cancer event, last contact
11 on criteria for the occurrence of a thrombotic event, which were censored at hospital discharge or 30 days after PCC admi
12                                                    Patients were censored at postdischarge emergency department encounter
13 analysis, when patients who received SCT in first remission were censored at SCT time, 2-year RFS was 53.3% (95% CI, 39%
14       A total of 1975 patients received a successful KT and were censored at that point, whereas 1876 were on the waiting
15                         Eyes that developed neovascular AMD were censored at the day of its detection.
16                                                 Individuals were censored at the earliest of death, first relapse, loss t
17 were developed to predict major bleeding risk; participants were censored at the earliest of the date on which they first
18               Patients who had not switched to chemotherapy were censored at the last follow-up date (median of 36 mo; ra
19 (6.2%) for whom the 30-day follow-up was incomplete and who were censored at the last follow-up time.
20                Results All patients in the N3I3 arm (n = 6) were censored at the time of analysis as a result of dose-lim
21                                           When participants were censored at the time of cointerventions (parathyroidecto
22 tural history, patients undergoing aortic valve replacement were censored at the time of surgery (n=92).
23 m birth and death dates; children living on March 31, 2013, were censored at their last clinical encounter.
24             Patients who continued, alive and relapse free, were censored at their last known follow-up.
25  in the standard care group had been lost to follow-up, and were censored at their last visit for the primary analysis.
26                              Data for patients on treatment were censored at this timepoint.
27                                                Observations were censored at trial discontinuation for reasons other than
28                                                 No patients were censored before 1 year (median follow-up period 438 days
29                                                        Data were censored both at the time of transplantation (listed onl
30 icipants in the placebo group and 22 in the treatment group were censored, but all contributed data for the final analysi
31 f these women had died, 1118 (52%) were alive, and 159 (7%) were censored early.
32  survival was 13.8 months (95% CI 11.1-29.3); however, data were censored for 48 patients (66%).
33                                                Participants were censored for a new diagnosis of a uveitis-associated sys
34                                                    Patients were censored for death with LVAD at the time of transplant o
35 , assessed in all participants who received treatment (data were censored for those lost-to-follow-up or who died).
36             In patients who received rescue treatment, data were censored from the time rescue treatment was given.
37                                                Outcome data were censored if no CCHS encounters occurred for 2 consecutiv
38  (FCTA) at our center between April 2009 and May 2011; data were censored in June 2012.
39                          Five hundred seventy-four patients were censored in the original analysis owing to incomplete vi
40          Patients who underwent additional glaucoma surgery were censored in the survival analysis.
41                                              Follow-up data were censored on December 13, 2011.
42                    Patients were followed up until death or were censored on December 31, 2013.
43                                  Patients lost to follow-up were censored on the date of their last follow-up.
44 ndary outcomes [eg, new non-recrudescent malaria infection] were censored on the last day of follow-up), and per-protocol
45 sychiatric setting for any mental disorder; 489,006 persons were censored owing to death; and 69,987 persons were censore
46 06 persons were censored owing to death; and 69,987 persons were censored owing to emigration.
47 is in which data for patients who underwent transplantation were censored, the benefit of midostaurin was consistent acro
48                                                 Animal data were censored to simulate prospective monitoring at any momen
49                                                    Patients were censored upon treatment with a different anti-VEGF medic
50                     Eyes were considered to have failed and were censored when additional SLT or glaucoma surgery was per